For Immediate Release
Chicago, IL – April 6, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: J&J (JNJ - Free Report) , Sanofi (SNY - Free Report) , AstraZeneca (AZN - Free Report) , Lilly (LLY - Free Report) and Merck (MRK - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Pharma Stock Roundup: Race to Coronavirus Treatments, Cures
This week J&J selected a lead vaccine candidate for the treatment of coronavirus disease, COVID-19. Sanofi treated the first patient in an outside U.S. study on its and Regeneron’s rheumatoid arthritis (RA) drug, Kevzara for patients hospitalized with severe COVID-19. Meanwhile, the FDA approved AstraZeneca’s Imfinzi for its third indication, an aggressive form of lung cancer and Lilly’s IL-17 inhibitor, Taltz for plaque psoriasis in pediatric patients.
Recap of the Week’s Most Important Stories:
J&J Identifies Coronavirus Vaccine Candidate: J&J announced that it has identified a lead vaccine candidate for COVID-19 and expects to begin phase I human clinical studies on the same by September. J&J also announced a new partnership with BARDA and committed to provide global supply of more than one billion doses of the vaccine. J&J sounded confident of having the first batches of a COVID-19 vaccine available for emergency use authorization by early 2021. Earlier J&J had committed to invest more than $1 billion to co-fund vaccine research, development, and clinical testing along with BARDA.
Sanofi Starts Outside U.S. Study on Kevzara for Severe Coronavirus Infection: Sanofi announced the initiation of a phase II/III study outside theUnited States to evaluate IL-6 inhibitor, Kevzara to treat patients hospitalized with severe infection due to COVID-19. The study has been initiated in Italy, Spain, Germany, France, Canada and Russia and is enrolling patients immediately. The first patient in the study has been treated. Last month, Regeneron/Sanofi announced plans to study Kevzara for severe COVID-19 infection. Regeneron initiated a U.S. based phase II/III study last month. While Regeneron is leading the U.S. studies, Sanofi is taking care of the ex-U.S. studies.
FDA Approves AstraZeneca’s Imfinzi for Aggressive Lung Cancer Indication: The FDA granted approval to AstraZeneca’s Imfinzi for the first-line treatment of extensive-stage small cell lung cancer —the most aggressive type of lung cancer —based on CASPIAN study data. The drug has been approved to treat this lung cancer patient population in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin. Regulatory filings are also under review in Europe and Japan. Imfinzi is presently marketed for second-line advanced bladder cancer and unresectable, stage III non-small cell lung cancer (NSCLC)
Meanwhile, on the recommendation from an independent Data Monitoring Committee (DMC), AstraZeneca said that a phase III DAPA-CKD outcomes study on its SGLT2 inhibitor, Farxiga will be stopped early. The phase III DAPA-CKD study is being conducted to see the effect of Farxiga on renal outcomes and cardiovascular (CV) mortality in patients with chronic kidney disease with or without type II diabetes. The DMC’s recommendation was based on Farxiga’s overwhelming efficacy in the above patient population. DAPA-CKD is part of AstraZeneca’s DapaCare clinical program to explore the CV and renal profile of Farxiga in type II diabetes patients. An sNDA seeking approval of Farxiga to reduce the risk of CV death or the worsening of heart failure (HF) in patients with reduced ejection fraction, with and without type-II diabetes is under priority review. The sNDA was based on positive results from the DAPA-HF study on Farxiga.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approving AstraZeneca’s hyperkalemia drug, Lokelma to treat patients on stable hemodialysis. The recommendation was based on data from phase IIIb DIALIZE study
FDA Approves Lilly’s Taltz for Pediatric Patients: The FDA approved Lilly’s Taltz to treat pediatric patients (aged from six to below 18 years) with moderate-to-severe plaque psoriasis. Taltz, an important revenue driver for Lilly, is presently marketed for moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in adults.
Meanwhile, Lilly announced a collaboration with small biotech, Sitryx to study up to four novel preclinical targets, identified by the latter, which can be developed into new medicines for autoimmune diseases. For the research and license collaboration, Lilly will make an upfront payment of $50 million to Sitryx while also investing $10 million in its stock.
Merck’s Keytruda Meets PFS Endpoint in MSI-H Colorectal Cancer Study: Merck’s phase III head-to-head study (KEYNOTE-177) comparing Keytruda monotherapy to standard-of-care chemotherapy for the first-line treatment for MSI-H or dMMR colorectal cancer met one of its dual primary endpoints of progression-free survival (PFS). The data from an interim analysis showed that treatment with Keytruda led to statistically significant improvement in PFS over chemotherapy, including the current standard of care regimen of mFOLFOX6 plus Avastin (bevacizumab) in the above patient population. The interim analysis was conducted by an independent DMC. The DMC recommended the study to be continued without changes to evaluate the other primary endpoint, overall survival.
EU Approval for Bayer’s Nubeqa and Pfizer Ruxience: The European Commission (EC) granted marketing approval to Bayer’s Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa was approved by the FDA in August last year, three months ahead of its target action date. Nubeqa has been developed jointly by Bayer and Finnish pharma company, Orion Corporation.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.